EpaleX is a specialty pharmaceutical development company with the mission of creating investor value by inventing innovative new therapies that provide an improved quality of life for patients with neurological disorders.
Inhaled treatments to stop seizures and migraine before they spread.
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
EpaleX is developing a range of molecules and is the licensee of two issued U.S. patents covering the chemical composition of the active ingredient in a lead product and the uses of this active ingredient in epilepsy and migraine.
Initial product development was supported by research grants from the Epilepsy Therapy Project and the Epilepsy Foundation. Current development is supported by the National Institutes of Health through the National Center for Advancing Translational Sciences.
The potential United States market for this product include an estimated 200,000 people with epilepsy and a substantial number of the estimated 35 million Americans with migraine.
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
EpaleX is developing a range of molecules and is the licensee of two issued U.S. patents covering the chemical composition of the active ingredient in a lead product and the uses of this active ingredient in epilepsy and migraine.
Initial product development was supported by research grants from the Epilepsy Therapy Project and the Epilepsy Foundation. Current development is supported by the National Institutes of Health through the National Center for Advancing Translational Sciences.
The potential United States market for this product include an estimated 200,000 people with epilepsy and a substantial number of the estimated 35 million Americans with migraine.
